Doctor of Podiatric Medicine Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Benjamin Savasky

Podiatrist Irvine, CA Doctor of Podiatric Medicine

NPI 1700240090 CMS profile 8149536

25 Gardenpath, Irvine, CA 92603

Open in the dashboard

General payments

$16,555

166 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Benjamin Savasky of Irvine, CA is reported in the CMS Open Payments database as having received $16,555 across 166 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Podiatrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $180 2
2024 General $3,869 24
2023 General $1,331 20
2022 General $3,862 32
2021 General $4,894 67
2020 General $2,419 21

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Benjamin Savasky
  • Podiatrist median
  • Middle half of Podiatrist
  • National median

In program year 2025, general payments to Benjamin Savasky were reported at $180. Among 4,572 Podiatrist profiles paid that year, the median was $260 and the middle half received between $94 and $777.

Show as a table
Year Benjamin Savasky Podiatrist median Middle half National median
2019 $0 $196 $72–$601 $163
2020 $2,419 $118 $38–$335 $114
2021 $4,894 $169 $57–$573 $132
2022 $3,862 $220 $74–$782 $149
2023 $1,331 $208 $71–$635 $160
2024 $3,869 $237 $87–$681 $164
2025 $180 $260 $94–$777 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Stryker Corporation $13,360 138 payments
  2. Bioness Inc $1,245 3 payments
  3. Musculoskeletal Transplant Foundation Inc. $527 6 payments
  4. DePuy Synthes Sales Inc. $341 5 payments
  5. Nevro Corp. $269 3 payments
  6. Integra LifeSciences Corporation $235 3 payments
  7. Bioventus LLC $151 2 payments
  8. TissueTech, Inc. $139 1 payment
  9. Saxum Surgical, Inc. $106 1 payment
  10. Paragon 28, Inc. $85 1 payment
  11. Other $99 3 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $9,417 145 payments
  2. Travel and Lodging $6,031 19 payments
  3. Entertainment $598 1 payment
  4. Education $510 1 payment
Products named General payments · program years 2020–2025
  1. AUGMENT INJECTABLE $2,571 20 payments
  2. INBONE $2,525 14 payments
  3. PROSTEP $2,130 14 payments
  4. AXSOS $1,614 4 payments
  5. FIXOS $1,599 6 payments
  6. HOFFMANN $1,430 30 payments
  7. Stimrouter for Pain $1,245 3 payments
  8. SONICANCHOR $964 12 payments
  9. ANCHORAGE $918 4 payments
  10. ASNIS $744 2 payments
  11. Other $7,957 111 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

796

Median for Podiatry: 160

Drug cost

$10,781

Median for Podiatry: $2,368

Branded share of claims

12.2%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ammonium Lactate Generic 163 $3,026
Terbinafine Hcl Generic 154 $2,602
Clotrimazole-Betamethasone Clotrimazole/Betamethasone Dip Brand 73 $1,326
Ketoconazole Generic 39 $960
Gabapentin Generic 100 $774
Methylprednisolone Generic 99 $569
Diclofenac Sodium Generic 33 $516
Ciclopirox Generic 14 $316
Doxycycline Hyclate Generic 58 $293
Ondansetron Odt Ondansetron Brand 13 $157

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 47 billing codes

Paid by Medicare

$699,247

Medicare's payments for the services billed

Medicare patients

86

Average age 74

Services billed

913

45 women, 41 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 65%
Arthritis 52%
Chronic kidney disease 45%
Ischemic heart disease 40%
Heart failure 38%
Atrial fibrillation 29%
Depression 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

166 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record